CorMedix Inc
NASDAQ:CRMD
Net Margin
CorMedix Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
CorMedix Inc
NASDAQ:CRMD
|
759.7m USD |
21%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
751.6B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.3B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.5B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
184.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
13%
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CorMedix Inc's most recent financial statements, the company has Net Margin of 20.8%.
You don't have any saved screeners yet